Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
Inflammatory Bowel Disease
•
LFT abnormalities
•
JAK Inhibitors
•
Gastroenterology
•
General Hepatology
•
Primary Care
Would you prescribe a JAK inhibitor in patients with baseline transaminase elevation?
Related Questions
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
How do you approach the management of a patient with RA on methotrexate who has gingivitis or or frequent cavities?
In patients with longstanding UC or Crohn's colitis, would you extend the interval of surveillance colonoscopy to longer than 3 years if they have had little inflammatory disease over the years and no other factors to increase their risk (ie, history of polyps, history of dysplasia, or family history)?
How do you approach the treatment of Crohn's colitis in the setting of immunosuppression for liver transplant?
What role do you feel there is for antibiotics in the management of severe perianal Crohn's disease?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
How do you choose between resmetirom and semaglutide in the treatment of MASH?
